Follicular lymphoma -- typically a slow-growing or indolent form of non-Hodgkin lymphoma that arises from B lymphocytes -- accounts for 20% to 30% of all non-Hodgkin lymphoma cases.

Researchers at University of Tsukuba have identified multiple T-cell subtypes with unique characteristics in follicular lymphoma, a prevalent type of blood cancer. These T cells regulate the ...

Gastrointestinal follicular lymphoma (GI‐FL) is a rare, indolent B‐cell neoplasm that predominantly affects the small intestine, particularly the duodenum, although cases have been reported ...

Follicular lymphoma -- typically a slow-growing or indolent form of non-Hodgkin lymphoma that arises from B lymphocytes -- accounts for 20% to 30% of all non-Hodgkin lymphoma cases. The indolent ...

This trial compared ofatumumab with rituximab for people with diffuse large B cell or follicular lymphoma.

Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, offering a dual-targeting strategy to enhance the therapeutic efficacy of monoclonal antibodies, which is often limited by ...

Label changes remove Risk Evaluation and Mitigation Strategy programs and eases monitoring requirements, supporting broader access to Bristol Myers Squibb’s CAR T-cell therapies Breyanzi and Abecma ...

Many factors can affect lymphoma outlook, including the type, stage and spread of cancer, and a person's age and overall health. Read about lymphoma survival here.

Find information on cost and Epkinly, how generic and brand-name prices compare, what financial assistance may be available, and more.

Treatments for non-Hodgkin lymphoma, a cancer of white blood cells, include chemotherapy, immunotherapy, radiation therapy, and stem cell transplants, with the specific approach depending on the ...

Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire- Three-decade industry leader, former CEO of Karuna and Anthos and Chief Commercial Officer of Allergan, Bill Meury ...